Company news
Sunshine Lake Pharma Co., Ltd. news in 2026
Sunshine Lake Pharma Co., Ltd.'s news releases, calls and decks from 2026, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 4, 2026
Change of company secretary, authorized representative and process agent
October 30, 2026
Voluntary announcement Insulin Degludec and Insulin Aspart Injection obtained marketing approval from the china national medical products administration
October 8, 2026
Next Day Disclosure Return
October 2, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
Interim Report 2026
September 30, 2026
Next Day Disclosure Return
September 29, 2026
Next Day Disclosure Return
September 28, 2026
Inside information filing with the CSRC in relation to the proposed implementation of h share full circulation
September 23, 2026
Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
May 4, 2026